San Francisco, United States
Menten AI is at the forefront of leveraging Generative AI to transform the realm of biotechnology by developing cyclic peptide therapeutics. Their innovative approach targets drug areas previously unattainable by traditional small molecules and biologics. Through their proprietary platform, MAUD 1.0, Menten AI facilitates the rapid synthesis of macrocycles that exhibit desirable drug-like attributes, including oral bioavailability and cell permeability.
Founded in 2020 and headquartered in the United States, Menten AI has made substantial strides in the pharmaceutical industry by collaborating with top-tier companies such as Bristol Myers Squibb. They are bolstered by significant investment from firms like Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator. Their last investment was a Seed Round on 05 May 2023, with participation from investors like big_bets and Sahin Boydas. Positioned within diverse industries—spanning AI to Life Sciences—Menten AI is poised to drive advancements in health care innovation.
